KCT0005149进行中（未招募）未知
Bendamustine plus rituximab for mantle cell lymphoma: a multicenter retrospective analysis
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Patients with newly diagnosed mantle cell lymphoma diagnosed by a pathologist (based on the 2016 revised WHO classification criteria)
- •1) mantle cell lymphoma
- •2) leukemic nonnodal mantle cell lymphoma
- •3) in situ mantle cell neoplasia
- •2. Age = 19 years old
- •3. Includes both patients treated with bendamustine/rituximab combination therapy for initial treatment and patients treated with bendamustine/rituximab combination therapy for relapse/refractory treatment.
排除标准
- •1. Patients unable to provide clinical and pathological data
- •2. Patients not treated with the bendamustine/rituximab combination
研究者
相似试验
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS
已完成
2 期
Phase II trial of bendamustine plus rituximab treatment for relapsed or refractory low grade B-cell non Hodgkin lymphomaJPRN-UMIN000005386Kanagawa Clinical Oncology study Group44
已完成
2 期
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaAggressive LymphomaNCT01686321University of Göttingen68
进行中（未招募）
2 期
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaMantle Cell LymphomaNCT01661881Christine Ryan23
已完成
2 期
Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapyuntreated and advanced follicular lymphomaJPRN-UMIN000013795Department of Hematology and Rheumatology,Kinki University Faculty of Medicine60